New Chemical Modalities and Strategic Thinking in Early Drug Discovery

被引：81

作者：

Blanco, Maria-Jesus ^{[1
]}

Gardinier, Kevin M. ^{[2
]}

机构：

[1] Sage Therapeut Inc, Med Chem, 215 First St, Cambridge, MA 02142 USA

[2] Novartis Inst BioMed Res, Global Discovery Chem, 22 Windsor St, Cambridge, MA 02139 USA

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2020年 / 11卷 / 03期

关键词：

Chemical modalities; RNA; PROTAC; cyclopeptides; target validation; strategy; TARGET;

D O I：

10.1021/acsmedchemlett.9b00582

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The classical toolbox for drug discovery is continuously expanding beyond traditional small molecules. New chemical modalities including RNA therapeutics, protein degraders, cyclopeptides, antibody drug conjugates, and gene therapy have matured, demonstrating clinical success and are now considered early in target appraisal. In this Viewpoint, we highlight recent progress in the field.

引用

页码：228 / 231

页数：4

共 20 条

[1] 2018 FDA Tides Harvest
Al Shaer, Danah
Al Musaimi, Othman
Albericio, Fernando
de la Torre, Beatriz G.
[J]. PHARMACEUTICALS, 2019, 12 (02)
[2] Evaluating the Role of Macrocycles in the Susceptibility of Hepatitis C Virus NS3/4A Protease Inhibitors to Drug Resistance
Ali, Akbar
Aydin, Cihan
Gildemeister, Reinhold
Romano, Keith P.
Cao, Hong
Oezen, Ayseguel
Soumana, Djade
Newton, Alicia
Petropoulos, Christos J.
Huang, Wei
Schiffer, Celia A.
[J]. ACS CHEMICAL BIOLOGY, 2013, 8 (07) : 1469 - 1478
[3] Know your target, know your molecule
Bunnage, Mark E.
Gilbert, Adam M.
Jones, Lyn H.
Hett, Erik C.
[J]. NATURE CHEMICAL BIOLOGY, 2015, 11 (06) : 368 - 372
[4] Antibody-Drug Conjugates and Small Molecule-Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic Agents
Casi, Giulio
Neri, Dario
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (22) : 8751 - 8761
[5] The Next Phase of Human Gene-Therapy Oversight
Collins, Francis S.
Gottlieb, Scott
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (15) : 1393 - 1395
[6] Peptide-Cleavable Self-immolative Maytansinoid Antibody-Drug Conjugates Designed To Provide Improved Bystander Killing
Costoplus, Juliet A.
Veale, Karen H.
Qiu, Qifeng
Ponte, Jose F.
Lanieri, Leanne
Setiady, Yulius
Dong, Ling
Skaletskaya, Anna
Bartle, Laura M.
Salomon, Paulin
Wu, Rui
Maloney, Erin K.
Kovtun, Yelena V.
Ab, Olga
Lai, Kate
Chari, Ravi V. J.
Widdison, Wayne C.
[J]. ACS MEDICINAL CHEMISTRY LETTERS, 2019, 10 (10): : 1393 - 1399
[7] Targeting RNA with Small Molecules To Capture Opportunities at the Intersection of Chemistry, Biology, and Medicine
Disney, Matthew D.
[J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2019, 141 (17) : 6776 - 6790
[8] Target Engagement in Lead Generation
Durham, Timothy B.
Blanco, Maria-Jesus
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (05) : 998 - 1008
[9] Why Some Targets Benefit from beyond Rule of Five Drugs
Egbert, Megan
Whitty, Adrian
Keseru, Gyorgy M.
Vajda, Sandor
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (22) : 10005 - 10025
[10] Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, SM
Harborth, J
Lendeckel, W
Yalcin, A
Weber, K
Tuschl, T
[J]. NATURE, 2001, 411 (6836) : 494 - 498

← 1 2 →